Beam Therapeutics Inc. (BEAM)
24.12
0.00 (0.00%)
Upcoming Events
Latest Headlines
Beam Therapeutics shares updated BEAM-302 trial data at ERS 2026
September 8, 2026 6:00 AM - StreetInsider
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
September 8, 2026 6:00 AM - StreetInsider
Beam Therapeutics names Eric Foster as chief commercial officer
September 1, 2026 7:00 AM - StreetInsider
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
September 1, 2026 7:00 AM - StreetInsider
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
August 31, 2026 7:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
August 25, 2026 6:58 AM - StreetInsider
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC
August 14, 2026 2:56 PM - SEC Filing
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 13, 2026 5:14 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
August 10, 2026 6:43 AM - StreetInsider
Beam Therapeutics Inc (BEAM) PT Raised to $240 at JPMorgan
August 5, 2026 8:11 AM - StreetInsider
Form 10-Q Beam Therapeutics Inc. For: Jun 30
August 4, 2026 7:14 AM - SEC Filing
Beam, Inc. (BEAM) Misses Q2 EPS by 8c
August 4, 2026 7:14 AM - StreetInsider
Form 8-K Beam Therapeutics Inc. For: Aug 04
August 4, 2026 7:09 AM - SEC Filing
Beam Therapeutics posts Q2 loss, doses first patient in BEAM-302 trial
August 4, 2026 7:00 AM - StreetInsider
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
August 4, 2026 7:00 AM - StreetInsider
Form 4 Beam Therapeutics Inc. For: Jul 27 Filed by: Simon Amy
July 29, 2026 4:05 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Simon Amy
July 27, 2026 4:05 PM - SEC Filing
Beam Therapeutics to present BEAM-302 trial data at ERS 2026
July 23, 2026 7:00 AM - StreetInsider
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congres
July 23, 2026 7:00 AM - StreetInsider
TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'
July 8, 2026 12:30 PM - StreetInsider
BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff
July 8, 2026 11:32 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
July 7, 2026 7:03 AM - StreetInsider
Form 4 Beam Therapeutics Inc. For: Jun 30 Filed by: Simon Amy
July 2, 2026 4:05 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Jun 29 Filed by: Evans John M.
July 1, 2026 4:05 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
June 30, 2026 4:19 PM - SEC Filing
Form 144 Beam Therapeutics Inc. Filed by: Evans John M.
June 29, 2026 4:15 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Jun 25 Filed by: FMR LLC
June 29, 2026 2:17 PM - SEC Filing
Form 4 Beam Therapeutics Inc. For: Jun 17 Filed by: Ciaramella Giuseppe
June 22, 2026 4:05 PM - SEC Filing
FDA clears Beam Therapeutics IND for PKU gene editing therapy
June 18, 2026 7:00 AM - StreetInsider
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
June 18, 2026 7:00 AM - StreetInsider
Full Article List
